Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTarsus Regulatory News (TRS)

  • There is currently no data for TRS

Trading Statement

7 Jan 2008 07:00

Tarsus Group PLC07 January 2008 7 January 2008 TARSUS GROUP PLC TRADING UPDATE Tarsus Group plc ('Tarsus' or 'the Group'), the international media group withinterests in exhibitions, conferences, publishing and online media hascontinued to trade well in the second half of 2007 with strong performances fromall of its key products. Group like-for-like organic revenue growth for theyear to 31 December 2007 has been 15% and, as a result, the Board expects fullyear 2007 results to be towards the top end of market expectations. Labelexpo Europe, the Group's second largest exhibition, produced revenue growth10% above that of the 2005 event and rebookings for 2009 are already at 90% ofthe total 2007 event. The three important French exhibitions Heavent (event marketing), IP Convergence (IT) and Educatec (education) were all well ahead of2006 and contributed to strong like-for-like organic revenue growth from theFrench division of 14% for the year as a whole. The final medical event of theyear, Anti-Ageing Las Vegas, was a great success with revenues and attendees up35% and 30% respectively over 2006. The development of our emerging markets portfolio was significantly acceleratedwith the November 2007 acquisition of Fairs & Exhibitions Limited, whose keyevent is the Dubai Air Show. This biennial show, which is now the Group's largest, was extremely well received with visitor numbers up nearly 30% from the2005 event to 45,000 and record customer orders in excess of US$100 billion.The event will move to a new purpose-built venue in 2009 which has resulted inrequests for large upgrades in space from major exhibitors. Other emerging market events were China-focused in the second half and our keyevent, the third edition of Labelexpo Asia in Shanghai, saw revenues rise by12% above the 2005 event and visitor numbers by 54%. Rebookings are strong and well ahead of the previous cycle. Caroo, our online business, has continued its strong momentum with like-for-likeorganic revenues up by 21% for the full year. We have appointed a newdivisional CEO in the US to drive growth in that market following theacquisition of the DMS Group in July. Outlook for 2008 The broadening of the Group's base is an important step in underpinning ourability to grow consistently in the years ahead. During 2007 we have continuedto expand the number of sectors served by the Group and made good progress in diversifying our revenues geographically. Average emerging market revenues forthe 2007/2008 cycle are expected to be approximately 16% of the total up from5% for the 2005/2006 cycle. The Group is strongly second half weighted and, with the major Labelexpo showreturning to the US from Europe in 2008, dollar exposure will be higher than in2007. Our significant events in the first quarter of 2008 - the US Off-Price show, the Mod'Amont clothing accessories event in Paris and GESS (a neweducational show in Dubai) - are developing extremely well. Overall, forwardbookings are strong and the Board remains confident that 2008 will be anotheryear of strong like-for-like growth for the Group. The Group expects to announce its preliminary results for the year to 31December 2007 on 3 March 2008. Ends For further information please contact: Tarsus Group plc: Douglas Emslie: Group Managing Director: Tel 020 8846 2700 Media: Matthew Moth :Madano Partnership: Tel: 020 7593 4000 Investors: Neville Harris : IRFocus: Tel: 020 7593 4215 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
16th May 20197:00 amRNSTrading Update
9th May 20196:19 pmRNSBlock Listing Six Monthly Return
30th Apr 201910:14 amRNSTotal Voting Rights
16th Apr 20192:40 pmRNSDirector/PDMR Shareholding
2nd Apr 20193:43 pmRNSBlock listing Interim Review
1st Apr 201910:44 amRNSTotal Voting Rights
19th Mar 201911:42 amRNS2018 Annual Report
8th Mar 20194:36 pmRNSPrice Monitoring Extension
27th Feb 20197:00 amRNSFinal Results
6th Feb 20194:35 pmRNSPrice Monitoring Extension
31st Jan 201911:53 amRNSTotal Voting Rights
30th Jan 20197:00 amRNSOption agreement re Tarsus Connect
16th Jan 20194:22 pmRNSApplication for Admission
14th Jan 20197:00 amRNSYear-end Trading Update
13th Dec 20184:48 pmRNSScrip Dividend Circular (the "Circular")
30th Nov 20183:10 pmRNSTotal Voting Rights
20th Nov 20181:44 pmRNSApplication for Admission
6th Nov 20187:00 amRNSCapital Markets Seminar and Trading Update
1st Nov 20182:56 pmRNSTotal Voting Rights
18th Sep 20186:20 pmRNSDirector/PDMR Shareholding
14th Sep 201812:06 pmRNSResults of Placing
14th Sep 20187:00 amRNSAcquisitions and Placing of New Ordinary Shares
10th Sep 20183:18 pmRNSBlock Listing Six Monthly Return
31st Aug 20183:39 pmRNSTotal Voting Rights
24th Aug 201811:17 amRNSHalf-year Report
1st Aug 201811:54 amRNSTotal Voting Rights
26th Jul 20187:00 amRNSHalf-year Report
13th Jul 20182:34 pmRNSApplication for Admission - scrip dividend shares
13th Jul 20182:18 pmRNSDirector Declaration
21st Jun 20181:52 pmRNSResult of AGM
18th Jun 20183:37 pmRNSHolding(s) in Company
12th Jun 20184:41 pmRNSDirector/PDMR Shareholding
8th Jun 20183:45 pmRNSScrip Dividend Circular
1st Jun 201812:31 pmRNSTotal Voting Rights
21st May 20186:10 pmRNSNotice of AGM
17th May 20187:00 amRNSTrading Update
9th May 20187:00 amRNSBoard Changes
9th May 20187:00 amRNSBlock Listing Six Monthly Return
1st May 201811:45 amRNSTotal Voting Rights and Capital
20th Apr 201812:15 pmRNSDirector/PDMR Shareholding
20th Apr 201812:14 pmRNSDirector/PDMR Shareholding
18th Apr 20184:29 pmRNSNotification of Transactions
29th Mar 201810:50 amRNSTotal Voting Rights
22nd Mar 20185:01 pmRNS2017 Annual Report
9th Mar 20183:54 pmRNSDirector/PDMR Shareholding
6th Mar 201810:18 amRNSBlock Listing Six Monthly Return
5th Mar 20185:06 pmRNSDirector/PDMR Shareholding
28th Feb 20187:00 amRNSFinal Results
31st Jan 20189:40 amRNSTotal Voting Rights
12th Jan 201810:30 amRNSApplication for Admission - scrip dividend shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.